Breast cancer survivors who eat a healthy diet and exercise moderately can reduce their risk of dying from breast cancer by half, regardless of their weight, suggests a new longitudinal study from the Moores Cancer Center at the University of California, San Diego (UCSD).
Women on tamoxifen therapy who reported having hot flashes were less likely to develop recurrent breast cancer than those who did not report hot flashes, according to a study from the Moores Cancer Center at the University of California, San Diego (UCSD).
The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial being presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.
An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.
When women under 50 develop breast cancer the disease tends to be more aggressive and less responsive to treatment than when it occurs in older women.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
GlaxoSmithKline (NYSE: GSK) announced positive data from three key studies on its first-in-class, oral small molecule HER2 kinase inhibitor, Tykerb (lapatinib).
Despite modest overall improvements in breast cancer survival rates for women with advanced disease over the last two decades, the rates for black women have not improved and the difference in life expectancy between white and black women continues to widen, according to researchers at the University of Texas M. D. Anderson Cancer Center.
A unique examination of one treatment center?s use of magnetic resonance imaging (MRI) in new breast cancer patients has found MRI to be superior to mammography in finding additional tumors in a breast in which cancer has already been diagnosed, and in detecting new tumors in a patient?s supposedly healthy breast.
GEMZAR? (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol?) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study presented with encouraging results in the pre-surgical treatment of breast cancer.